Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas (NEONEC)
Phase II Study to Evaluate the Efficacy of 12-month Neoadjuvant Chemotherapy in Terms of Disease-free Survival in Patients With Localized Digestive Neuroendocrine Carcinomas
Sponsor: Fondation ARCAD
This PHASE2 trial investigates Digestive Cancer and Neuroendocrine Carcinoma and is currently actively recruiting participants. Fondation ARCAD leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Aug 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Sep 2021 — Apr 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fondation ARCAD
- GERCOR - Multidisciplinary Oncology Cooperative Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Besançon, France , Clichy, France , Dijon, France , Lyon, France , Marseille, France , Paris, France , Pessac, France , Poitiers, France , Toulouse, France and 1 more location